Showing results (271-280 of 345) with videos related to
Sort By:
Pageof 35
Emergency Medicine Journal : EMJ|August 10, 2021
Prehospital risk stratification in patients with chest painDennis Sagel, Pieter Jan Vlaar, Radboud van Roosmalen, et al.European Journal of Heart Failure|May 16, 2019
The clinical significance of interleukin-6 in heart failure: results from the BIOSTAT-CHF studyGeorge Markousis-Mavrogenis, Jasper Tromp, Wouter Ouwerkerk, et al.Journal of the American College of Cardiology|October 27, 2025
Effect of Acoramidis on Recurrent and Cumulative Cardiovascular Outcomes in ATTR-CM: Exploratory Analysis From ATTRibute-CMAhmad Masri, Daniel P Judge, Frederick L Ruberg, et al.ESC Heart Failure|April 1, 2018
Prevalence, clinical correlates, and outcomes of anaemia in multi-ethnic Asian patients with heart failure with reduced ejection fractionVera J Goh, Jasper Tromp, Tiew-Hwa K Teng, et al.European Journal of Heart Failure|December 29, 2019
Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failurePiotr Ponikowski, Bridget-Anne Kirwan, Stefan D Anker, et al.International Journal of Cardiology|January 8, 2018
Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failureJozine M Ter Maaten, Adriaan A Voors, Kevin Damman, et al.European Journal of Heart Failure|April 4, 2020
A network analysis to identify pathophysiological pathways distinguishing ischaemic from non-ischaemic heart failureIziah E Sama, Rebecca J Woolley, Jan F Nauta, et al.European Journal of Heart Failure|November 7, 2023
Sacubitril/valsartan compared to ramipril in high-risk post-myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists: Insight from the PARADISE MI trialMorten Schou, Brian Claggett, Zi Michael Miao, et al.Scientific Reports|June 20, 2020
The phospholamban p.(Arg14del) pathogenic variant leads to cardiomyopathy with heart failure and is unreponsive to standard heart failure therapyTim R Eijgenraam, Bastiaan J Boukens, Cornelis J Boogerd, et al.Journal of the American College of Cardiology|September 1, 2024
Effect of Semaglutide on Cardiac Structure and Function in Patients With Obesity-Related Heart FailureScott D Solomon, John W Ostrominski, Xiaowen Wang, et al.Pageof 35